DYN - Conference and earnings call announcements

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NYGoldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL A li

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA2026 Jefferies Biotech on the Beach Summit, hosting meetings on Tuesday, March 10 and Wednesday, March 11, 2026 in Miami, FLStifel 2026 Virtual CNS Forum, virtual fireside chat on Tuesday, March 17, 2026 at 4:00 p.m. ET A live webcast of each fire

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days. About Dyne TherapeuticsDyne Therapeutics i

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Monday, November 10, 2025 at 10:00 a.m. ET in Boston, MAStifel 2025 Healthcare Conference, fireside chat on Tuesday, November 11, 2025 at 9:20 a.m. ET in New York, NYJefferies Global Healthcare Conference, fireside chat on Monday, November 17, 2025 at 3:00 p.m. GMT (10:00 a.m. ET) in London8th A

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences: Cantor Global Healthcare Conference 2025, fireside chat on Friday, September 5, 2025 at 9:45 a.m. ET in New YorkMorgan Stanley 23rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025 at 9:15 a.m. ET in New York A live webcast of each presentation will be available in the Investors & Media section of Dyne's website at https://investor

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is discovering and advanc

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Ther

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the pre

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences: Guggenheim Inaugural Healthcare Innovation Conference, fireside chat on Wednesday, November 13, 2024 at 4:00 p.m. ET in BostonStifel 2024 Healthcare Conference, fireside chat on Tuesday, November 19, 2024 at 3:00 p.m. ET in New YorkPiper Sandler 36th Annual Healthcare Conference, fireside chat on Tuesday, December 3, 2024 at 3:00 p.m. ET in N

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeut

- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 -- Virtual Investor Event Today at 8:00 a.m. ET - WALTHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts. "We believe these data reinforce the opp

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics i

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and Timed Function Tests and in DM1-ACTIVc and MDHI Patient Reported Outcomes - - In Phase 1/2 DELIVER Trial, DYNE-251 Showed 3.2% Mean Unadjusted (7.6% Mean Muscle Adjusted) Dystrophin Expression at 6 Months in 10 mg/kg Cohort Administered Monthly; 10 Times Higher Level of Dystrophin Than Reported for Weekly Administered Standard of Care1- - DYNE-251 Demonstrated Trends in Functional Improvement in NSAA, Time to Rise from Floor, 10-Meter Walk/Run Time, and Stride Velocity 95th

WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET. This represents an update to Dyne's prior guidance for the second half of 2024. The company intends to issue a press release prior to the start of the event.  Phase 1/2 ACHIEVE Trial of DYNE-101 in DM1 ACHIEVE is a Phase 1/2 global clinical trial evaluating DYNE-101 i

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be a

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a clinical-st

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in February: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference, fireside chat on Thursday, February 8, 2024 at 11:00 a.m. ET in New York Oppenheimer 34th Annual Healthcare Life Sciences Conference, virtual fireside chat on Wednesday, February 14, 2024 at 2:40 p.m. ET A live webcast of each presentation will be available in the Investors & M

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presenta

WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November: Stifel 2023 Healthcare Conference, fireside chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York Piper Sandler 35th Annual Healthcare Conference, fireside chat on Tuesday, November 28, 2023 at 1:30 p.m. ET in New York A live webcast of each presentation will be available in the Investors & Media section of Dyne's website at https://in

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in October: Chardan's 7th Annual Genetic Medicines Conference, fireside chat on Tuesday, October 3, 2023 at 11:00 a.m. ET in New York Jefferies Inaugural Biotech CNS/Neuro Summit, fireside chat on Thursday, October 12, 2023 at 9:30 a.m. ET in New York A live webcast of each presentation will be available in the Investors & Media section of Dyne's website a

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference being held in New York on Monday, September 11, 2023 at 4:15 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Healthcare Conference in New York on Thursday, June 8, 2023 at 2:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a cl

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday, May 10, 2023 at 11:35 a.m. PT (2:35 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutic

WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences: Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 2:40 p.m. ETStifel 2023 CNS Days on Wednesday, March 29, 2023 at 11:30 a.m. ETGuggenheim Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023 at 10:10 a.m. ET A live webcast of each presentation will be available in the Investors & Media s

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2023 at 3:00 p.m. PT (6:00 p.m. ET). A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the prese

- DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 - WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2022 and business highlights. "In the third quarter of 2022 we marked incredibly important milestones for Dyne with the initiation of patient clinical trials for our two lead product candidates, DYNE-101 and DYNE-251. Individuals living with DM1 and DMD are in urgent need of new

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November: Credit Suisse 31st Annual Healthcare Conference, presentation on November 9, 2022 at 11:00 a.m. PT (2:00 p.m. ET) in Rancho Palos Verdes, CAJefferies London Healthcare Conference, fireside chat on November 16, 2022 at 12:20 p.m. GMT (7:20 a.m. ET) in LondonStifel 2022 Healthcare Conference, fireside chat on November 16, 2022 at 11:30 a.m. ET in

WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therape

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held in New York, NY on Monday, September 12, 2022 at 2:15 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About

WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 9, 2022 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics

- Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 -- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Planned in Mid-2022 - WALTHAM, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2021 and recent business highlights. "In 2021 we made significant achievements throughout the business. We generated platform-validating preclinical data across our

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation. About Dyne Therapeutics Dy

- Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne's Co-lead Candidates into the Clinic - - Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2021 and business highlights. "We made tremendous progress during the third quarter and are now preparing to advance

WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during Chardan's Virtual 5th Annual Genetic Medicines Conference. Joshua Brumm, Dyne's president and chief executive officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, will participate in a fireside chat on October 5, 2021 at 9:00 a.m. ET. A live webcast of the chat will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-pr

WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is building a leading muscle disease company ded

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of 2024 - WALTHAM, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter 2021 and business highlights. "We continued to make significant progress to start 2021, including generating new preclinical data in our DM1 program that will be featured during the upcoming ASGCT Annual Meeting, f

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the prese